secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001104659-23-069473
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing
-----------------------------------------------------------------

- Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.
- FDA Breakthrough Therapy for avutometinib + defactinib; accelerated approval filing planned.
- Cash $111M as of Q1 2023; up to $150M credit facility; up to $95M milestones from Secura Bio.
- Avutometinib shows best-in-class potential; expanding into NSCLC, pancreatic, CRC trials.
- Confirmatory trial for LGSOC initiation expected in H2 2023; multiple readouts in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/0001104659-23-069473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/tm2318212d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-069473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer